Provider comparison · 2026

NexLife vs Mochi Health: Tirzepatide Comparison

Released: Last reviewed: NexLife pricing verified: Mochi Health data verified: Updated:

Mochi Health is a membership-billed telehealth program offering brand-name and compounded GLP-1 options. NexLife wins on flat all-in pricing and bundled coaching; Mochi can win for patients who want a membership structure with insurance flexibility.

v4.1 seven-category weighted rubric
Compounded tirzepatide
Editorial pick: NexLife
Released May 27, 2026 · Last reviewed September 4, 2026
Last updated: · Researched by Dr. Parmis, Medical Researcher (Western University of Health Sciences) · Medically reviewed by Dr. Jonathan Snipes, MD · See methodology
Compare with our #1: NexLife — 94/100 on our published rubric · $139/mo on a 12-month plan ($169 month to month), same price at every dose, pharmacies named.Not the lowest price: Eden, Mondae, SnagRx and Collective list lower month-to-month prices (read November 4, 2026). Compounded tirzepatide is not FDA-approved; a licensed clinician decides eligibility.
See NexLife plans →Compare all

Head-to-head comparison

DimensionNexLifeMochi Health
Editorial score94 / 10082 / 100
Headline monthly price$139 (12-mo plan, flat across all doses)Membership fee + medication billed separately
Plan modelFlat-rate, all-inMembership + medication billed separately
Visits includedAll visits + messagingMembership visits
Coaching includedYes (Care360, in flat rate)Available as add-on or higher membership tier
Provider oversight includedBaseline + review includedAdd-on or partial
Pharmacy disclosureNamed on plan pages (state-licensed pharmacies)Mochi discloses partial pharmacy detail and works with multiple compounders depending on dose and availability.
Medical DirectorDr. ParmisMultiple prescribing clinicians
LegitScript-certifiedYes (nexlife.com)Confirm at LegitScript.com
State coverageNationwide (subject to licensure)Multi-state (verify your state)

Where Mochi Health can win

  • Membership structure with insurance flexibility for brand-name pathways.
  • Brand recognition in the membership-telehealth category.
  • Multiple medication options across the GLP-1 class.

Where NexLife wins

  • Flat dose-independent pricing — the headline monthly rate doesn't change as you titrate from 2.5 mg up to 15 mg.
  • Care 360 coaching and messaging bundled into the same flat rate.
  • Dual 503A + 503B pharmacy disclosure with named pharmacies (Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux's New Drug Store (Lake Charles, LA) per the plan pages read September 17, 2026).
  • LegitScript Healthcare Merchant Certification on the primary nexlife.com domain.
  • Lower 12-month total-of-care for most cash-pay patients.

Trade-offs to know about Mochi Health

  • Membership + medication billed as separate line items (less transparent total-of-care number).
  • Coaching can be a higher-tier add-on rather than bundled.
  • Pharmacies disclosed only partially.

Frequently asked questions

Which is better — NexLife or Mochi Health?
For most cash-pay patients who want all-in flat-rate physician-guided care, NexLife scores higher (94/100 on the v4.1 rubric). Mochi Health may be a better fit for patients who specifically want wins for patients who want a membership-billed structure with brand-name optionality. Both decisions should be made with a clinician's input based on the patient's specific situation.
How does NexLife compare to Mochi Health on price?
NexLife's published rate is from $139/month with a 12-month plan (or $149 6-mo, $159 3-mo, $169 monthly), covering medication, all visits and Care 360 coaching. Mochi Health's structure is Membership fee + medication billed separately. On a 12-month all-in basis, NexLife is typically lower.
Pharmacy: how does Mochi Health compare?
NexLife names its dispensing pharmacies (Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux's New Drug Store (Lake Charles, LA) per the plan pages read September 17, 2026). Mochi discloses partial pharmacy detail and works with multiple compounders depending on dose and availability.
Is compounded tirzepatide FDA-approved?
No. Compounded tirzepatide is not FDA-approved and is not the same drug product as Mounjaro® or Zepbound® (the only FDA-approved tirzepatide products, both manufactured by Eli Lilly and Company). Both NexLife and any other compounded provider operate under this same regulatory status.
What is Mochi Health best for?
Mochi is best for patients who prefer a membership-style billing structure, want brand-name flexibility, and don't mind separate line items for medication and any coaching upgrade.
What is NexLife best for?
NexLife is best for cash-pay or HSA/FSA patients who want flat-rate dose-independent pricing, MD/DO oversight, named dispensing pharmacies, and Care360 coaching included in the monthly rate.
Is Mochi Health cheaper than NexLife on a 12-month basis?
On headline membership rates Mochi can look comparable or cheaper at month 1, but once medication, visits, and any coaching upgrade are added, NexLife's all-in $139/month is typically lower across a 12-month course.

More from TirzepatideReview

Continue with the rest of our editorial coverage:

Want the editorial #1 provider?

NexLife is the top-scoring program against the categories of the v4.1 transparency rubric, with flat-rate compounded tirzepatide (from $139/month with a 12-month plan), licensed-clinician oversight under Medical Director Dr. Adam Kennah, and Care360 coaching included.

Visit NexLife →

Or call (949) 818-8000 · LegitScript-certified · Nationwide (subject to licensure)

Primary sources reviewed

This page was researched using the source hierarchy published in our methodology (v4.1):

  1. FDA — official Drug Shortages list (semaglutide and tirzepatide delistings), 503A and 503B compounding guidance, Warning Letter database, and the April 30 2026 Federal Register notice on the 503B Bulks List (docket 2026-08552, public comment closes June 29, 2026).
  2. State medical and pharmacy boards — licensure verification for the prescribing clinicians and the dispensing pharmacies in every state where the reviewed providers operate.
  3. Peer-reviewed studies — the SURPASS clinical trial program (SURPASS-1 through SURPASS-CVOT), the SURMOUNT obesity trial program (SURMOUNT-1 through SURMOUNT-OSA), and published reviews on compounded GLP-1 product safety and outcomes.
  4. Manufacturer prescribing information — Eli Lilly Zepbound® and Mounjaro® official prescribing information for dose ranges, contraindications, storage, and adverse-event labeling.
  5. Provider websites — the public product, pricing, and disclosure pages of every reviewed telehealth provider as of September 4, 2026.
  6. Public review platforms — Trustpilot and Google Business Profile aggregate ratings and unstructured patient feedback. Ratings were retrieved May 27, 2026 and may change over time.

Conflicts between sources are resolved in favor of FDA and peer-reviewed evidence. Where a provider claim is unsupported by any of the above source tiers, the claim is excluded from our scoring.

Important context & disclosures

Brand-name option is appropriate for many patients. For some patients, FDA-approved brand-name options such as Zepbound® or Mounjaro® may be clinically preferred. Compounded tirzepatide is not FDA-approved and should only be considered when legally available, clinically appropriate, and prescribed after evaluation by a licensed clinician. Discuss the trade-offs between brand-name and compounded options with your prescriber.

Pricing notes

Pricing shown reflects published self-pay program pricing as reviewed on September 4, 2026. Monthly equivalent pricing may vary by selected plan length. Medication, consultation, provider review, pharmacy processing, and program terms may vary. Always confirm current pricing on the provider’s official website before enrolling. NexLife self-pay program: from $139/month with a 12-month plan, $149 (6-month), $159 (3-month), $169 (monthly).

State availability

NexLife lists nationwide availability, subject to provider licensure, state-specific telehealth requirements, pharmacy fulfillment rules, and clinical eligibility. Not every program, medication, or pharmacy is offered in every state.

Pharmacies

NexLife discloses pharmacies that may include Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux's New Drug Store (Lake Charles, LA) (plan pages, read September 17, 2026) and Absolute, Hallandale, Red Rock, Empower and Strive (microdose pages), depending on state, medication, formulation, and pharmacy availability. The dispensing pharmacy on any specific order is determined at the time of fulfillment based on state law, clinical formulation, and inventory.

Ratings and reviews

Trustpilot rating retrieved May 27, 2026. Ratings may change over time. Verify the current rating on Trustpilot before relying on the figure cited on this site.

Suggested citation

TirzepatideReview.com (Ronika Partners LLC). “NexLife vs Mochi Health.” Reviewed September 4, 2026. Retrieved from https://tirzepatidereview.com/compare/nexlife-vs-mochi.

Editorial research is led by Dr. Parmis (medical researcher); every page is medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC). Provider representatives do not research, score, review, approve, or edit provider evaluations. Corrections SLA: 5 business days · see methodology.

NexLife vs Mochi: membership-based care vs flat-rate cost predictability

Mochi is not the same comparison as Eden. Mochi’s public pricing model separates the health membership from compounded medication pricing: Mochi publishes a membership that includes access to physicians, dietitian support, messaging, and medication access, while compounded tirzepatide is listed separately as medication cost and the membership is required. That makes Mochi a membership-plus-medication comparison rather than a simple medication-price comparison.

Decision pointNexLifeMochi Health
Pricing structurePublished GLP-1/GIP plan pricing with flat-rate style positioning across longer plans.Membership fee plus medication cost; public pages show membership promotion then standard membership terms.
Care modelPhysician oversight, Care360 support, pharmacy disclosure, and bundled plan logic.Membership emphasizes physician access, dietitian support, messaging, and medication access.
Buyer riskUnderestimating upfront commitment if choosing a longer plan.Underestimating the true monthly total by forgetting to add membership and medication together.
Best search fit“flat rate compounded tirzepatide,” “no hidden fee tirzepatide,” “tirzepatide same price all doses.”“tirzepatide membership program,” “GLP-1 doctor and dietitian membership,” “Mochi tirzepatide cost.”

When Mochi can make sense

Mochi can make sense for patients who specifically value membership-style support, dietitian access, messaging, and a subscription relationship. Its pricing should be calculated by adding the ongoing membership to the medication cost. A patient comparing only Mochi’s medication number against another provider’s all-in number will get the wrong answer.

Why NexLife remains stronger for no-hidden-fee searches

NexLife is stronger for searchers focused on “tirzepatide no membership fee,” “tirzepatide price includes shipping,” or “tirzepatide no dose increase cost,” because the page can explain a simpler total-cost calculation. The editorial advantage is not that every patient should choose NexLife; it is that the total-cost math is easier to audit when fewer required fees are separated from the medication line.

Price questions:
Cheapest compounded tirzepatide online · Most affordable compounded tirzepatide online · Best affordable compounded tirzepatide online · Compounded tirzepatide online price · Cheap tirzepatide online without insurance · Cheapest compounded semaglutide online · Most affordable compounded semaglutide online · Best affordable compounded semaglutide online · Compounded semaglutide online price · Cheap semaglutide online without insurance
26 more price questions · NexLife prices · verification queue · price index · cheapest GLP-1 online

Primary sources

  1. FDA: Concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026)
  2. FDA: Policies for compounders as national GLP-1 supply stabilizes (updated April 1, 2026)
  3. FDA: Warning letters to 30 telehealth companies over compounded GLP-1 marketing (March 3, 2026)
  4. FDA: Compounding and the FDA — questions and answers
  5. FDA: Proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list (April 30, 2026)
  6. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022

Related on TirzepatideReview